Background: Dextromethorphan (DM) / quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based on efficacy and safety trials in patients with PBA caused by amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia, or traumatic brain injury. Objective: To report results from the stroke cohort of PRISM II, including the Stroke Impact Scale (SIS). Design: Open-label trial evaluating twice-daily DM/Q over 90 days. Study participants: Adults (n = 113) with a clinical diagnosis of PBA secondary to stroke; stable psychiatric medications were allowed. Methods: PRISM II was an open-label, 12-week trial enrolling adults with PBA caused by dementia, stroke (reported here), or TBI. All study participants received DM/Q 20/10 mg twice daily. Study visits occurred at baseline and at days 30 and 90. Setting: 150 U.S. centers. Main Outcome Measurements: Primary efficacy measure was changed from baseline to day 90 in Center for Neurologic Study-Lability Scale (CNS-LS) scores. Secondary outcomes included PBA episodes (estimated over 7 days), Clinical and Patient/Caregiver Global Impression of Change (CGI-C and PGI-C), Quality of Life-Visual Analog Scale (QOL-VAS), SIS, Patient Health Questionnaire (PHQ-9), and Mini-Mental State Examination (MMSE). Results: Compared with baseline, CNS-LS scores (SD) improved by −6.2 (6.1, P < 0.001) at day 30 and − 7.6 (6.7, P < 0.001) at day 90. PBA episodes were reduced by 65% and 75% at day 30 and 90, respectively. Seventy-five percent of clinicians and 67% of patients/caregivers rated PBA as "much" or "very much improved." All SIS items significantly improved from baseline (P < 0.05, all). Adverse events included diarrhea (4.4%), headache (3.5%), constipation (2.7%), and dizziness (2.7%); 5.3% had adverse events leading to study discontinuation. Conclusions: DM/Q effectively treated PBA and was associated with global and functional improvement; adverse events were consistent with the known safety profile of DM/Q. Level of Evidence: I
Introduction
Stroke is a leading cause of disability and can result in significant, long-lasting neuropsychiatric sequelae, including apathy, depression, anxiety, post-traumatic stress disorder, irritability, impulsivity, mania, and psychosis, as well as pseudobulbar affect (PBA) [1, 2] . PBA is a disorder of emotional expression characterized by involuntary or exaggerated outbursts of laughing and/or crying that are independent or excessive to mood, social context, or provoking stimulus [3] [4] [5] . PBA has been reported after brain damage or disorders involving several anatomical regions, particularly lesions in the brain stem, internal capsule, and cerebellum [6] [7] [8] [9] . PBA episodes typically last seconds to minutes, can occur multiple times per day, and cannot be easily controlled by the individual. Such outbursts can be highly distressing to patients and others, leading to impaired social and occupational functioning and even social isolation [10, 11] .
PBA is estimated to affect up to 30% of stroke survivors following stroke; however, the condition remains underrecognized and often goes undiagnosed, even among patients who discuss symptoms with their doctors [2, 11, 12] . Systematic screening is not widely performed, and patients often fail to report episodes. Even when episodes are reported, they may be attributed to a mood disorder, such as depression, or a general sequelae of stroke [12] [13] [14] [15] . PBA diagnosis rates have been increasing in recent years, possibly due to better recognition, diagnostic understanding, and availability of treatment for PBA [10, [12] [13] [14] [15] [16] .
Currently, the fixed-dose combination of dextromethorphan (DM) 20 mg and quinidine (Q) 10 mg (NUEDEXTA; Avanir Pharmaceuticals, Inc, Aliso Viejo, CA) is the only Food and Drug Administration (FDA)-approved medication for PBA [17] . DM is a weak, uncompetitive Nmethyl-D -aspartate receptor antagonist, a moderate affinity sigma-1 receptor agonist, a serotonin and norepinephrine reuptake inhibitor, and an α3β4 neuronal nicotinic receptor antagonist [18] . When administered alone, DM typically undergoes rapid and extensive degradation by the cytochrome P450 2D6 (CYP2D6) enzyme to dextrorphan (DX), which is, in turn, rapidly glucuronidated and excreted, resulting in poor central nervous system bioavailability of both parent and metabolite [18] . Low-dose quinidine (Q), a potent CYP2D6 enzyme inhibitor, blocks the metabolism of DM, increasing systemic levels of DM approximately 20-fold and increasing DM half-life, while decreasing concentrations of DX. Thus, Q significantly increases the relative concentration of DM to DX and results in enhanced CNS concentrations of DM [17, 18] .
Controlled clinical trials demonstrated that DM/Q was an effective treatment for PBA in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS) and performed significantly better than placebo or DM or Q given alone [19] [20] [21] . Further, in a 1-year study of 553 patients with PBA caused by various neurologic conditions, including 51 (9.2%) patients with stroke, DM/Q 30/30 mg twice-daily (higher than the FDAapproved dose) safety and tolerability outcomes appeared consistent with the known morbidity of patient's primary neurologic conditions [22] .
The Pseudobulbar Affect Registry Investigating Symptom Management II (PRISM II) was designed to evaluate DM/Q effectiveness and safety for PBA treatment in patients with stroke, traumatic brain injury (TBI), or dementia-3 neurologic conditions that commonly cause PBA. Results from the overall study population (N = 367) as well as the cohort of PBA patients with dementia (n = 134) have been reported previously [23, 24] . Safety, tolerability, and efficacy results for the patients with PBA following stroke are reported here.
Methods

Study Design
PRISM II was an open-label, 90 day, multicenter U.S. trial (NCT01799941) enrolling adult patients with PBA caused by dementia, stroke, or TBI; the complete methodology has been described previously and is summarized only briefly here [25] . Patients received DM/Q 20/10 mg twice daily (once daily in week 1). Clinic visits occurred at baseline and at days 30 and 90 or early termination, with a phone visit at day 60.
Participants
Eligible patients had a stable neurologic condition for ≥3 months prior to enrollment. Patients in the stroke cohort were included if they were aged ≥18 years, had a clinical diagnosis of PBA based on published criteria [3] , which emerged following a stroke (ischemic or hemorrhagic), and had a Center for Neurological Study-Lability Scale (CNS-LS) score ≥ 13. Patients were allowed to continue concomitant medications, provided they were not contraindicated for use with DM/Q in the approved product labeling [25] and medication doses for dementia, mood, and behavioral symptoms were stable at baseline. Patients were excluded if they had severe dementia (Mini-Mental State Exam [MMSE] score < 10), recent stroke (within 3 months), penetrating TBI, severe depressive disorder, psychosis or bipolar disorder, resided in a mental health facility, had unstable medical illness, very short life expectancy (≤6 months), or any contraindication to DM/Q therapy.
Ethical conduct and informed consent
All procedures and protocols were approved by an institutional review board. All patients or caregivers provided written, informed consent. A caregiver was defined as a person who spent at least 3 to 4 days of waking hours with the patient for the week prior to clinic visits.
Outcomes
Primary Measure
The primary outcome was change from baseline to day 90 (or final visit) in CNS-LS score. The CNS-LS is a 7-item, PBA measure with scaled scores 7 (not present) to 35 (maximum severity and frequency), validated in MS and ALS [26, 27] . The CNS-LS was completed by the patient, or caregiver as patient proxy, at baseline, day 30 (visit 1), and day 90 or early withdrawal (final visit).
Secondary and Additional Measures
Several secondary measures were included to support the primary outcome. The number of PBA episodes during the 7 days prior to each study visit were recorded. The Clinician and Patient/Caregiver's Global Impression of Change (CGI-C and PGI-C, respectively), assessed overall change in the patient's PBA as reported by the investigator and patient (or caregiver), respectively, using a 7-item Likert-type scale, with 1 meaning "very much improved" and 7 meaning "very much worse" [28] . A Quality of Life-Visual Analog Scale (QOL-VAS) assessed the impact of PBA episodes on the patient's global subjective well-being during the prior week, using an anchored, continuous line scale, with 0 meaning "not at all affected" and 10 meaning "significantly affected." The Stroke Impact Scale (SIS), version 3.0, a self-report 59-item questionnaire, assessed stroke-related impairments across 8 domains of strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory, thinking, and participation, as well as an overall assessment of stroke recovery [29] . The Mini-Mental State Examination (MMSE), a widely used and validated scale, assessed cognition. The MMSE is scored from 0 to 30, with lower scores representing greater impairment (eg, MMSE <10 is severely impaired) [30] . Patient satisfaction with treatment was measured using a 5-item categorical scale ranging from very dissatisfied to very satisfied. The 9-item Patient Health Questionnaire (PHQ-9) was included as an additional measure to assess depressive symptoms; the PHQ-9 is scored from 0 to 27, with higher scores indicating more severe depression.
Safety
Safety was assessed via adverse event (AE) reporting. AEs were coded via Medical Dictionary for Regulatory Activities (MedDRA, version 15.1). Vital signs were recorded at clinic visits.
Statistical Analysis
All patients who met eligibility criteria for the stroke cohort, received at least 1 dose of DM/Q 20/10 mg, and had at least 1 postbaseline CNS-LS score were included in the effectiveness analyses population. The safety population included all patients who received at least 1 dose of DM/Q 20/10 mg. Missing data were not imputed; however, if the patient had a final visit, it was included as the day 90 visit. If there was no final visit, data from the day 30 visit were not carried forward as the final visit.
The primary analysis tested the null hypothesis that the mean change in CNS-LS score from baseline to the day 90 (or final visit, if not day 90) was equal to zero; 95% confidence intervals (CIs) were calculated to allow descriptive comparison with CNS-LS change observed in the phase 3, pivotal registration trial for DM/Q (STAR, NCT00573443) enrolling patients with PBA caused by MS or ALS [21] . A power analysis for a 1-sample t-test was used to determine that a sample size of 100 study participants with stroke would provide 80% power to detect a CNS-LS mean change of −7.45 points (increase of 1.75 points over assumed true placebo mean change of −5.7), or 90% power to detect a CNS-LS mean change of −7.7 points (increase of 2.0 points over assumed true placebo mean change).
Changes from baseline in effectiveness ratings were analyzed inferentially using parametric 1-sample t-tests for rating scale measures (CNS-LS, QOL-VAS, SIS, MMSE, and PHQ-9) and a mixed-effects Poisson regression model for percentage change from baseline in PBA episode count (along with P values and 95% CIs), with age, gender, and time (days 30 and 90) as fixed effects and baseline episode count as a variable effect. Tests of significance were 2-tailed with α set at 0.05. The percentage change in episode rate from baseline to a given visit was 1 minus the appropriate time parameter (λ). Safety data were summarized descriptively. All analyses were completed using either SAS v9.2 (SAS Institute Inc, Cary, NC) or Stata v12 (StataCorp, College Station, TX).
Results
Patient Disposition and Baseline Characteristics
The PRISM II stroke cohort enrolled 113 patients; all received at least 1 dose of DM/Q 20/10 mg, and 91 (80.5%) patients completed the study. The most common reasons for discontinuation were withdrawal of consent, adverse event (1 each: bradycardia, peripheral edema, urinary tract infection, lethargy, dysphonia, aspiration pneumonia, rash), or lost to follow-up (Figure 1) .
The mean age (SD) for the cohort was 60.5 (12.2) years, and most patients were female, white, and living at home (Table 1) . Most had a history of ischemic stroke and reported using at least 1 psychotropic medication. Mean baseline CNS-LS score was consistent with moderate to severe PBA (Table 1 ). Figure 1 . PRISM II stroke: patient disposition. CNS-LS, Center for Neurologic Study-Lability Scale; DM, dextromethorphan; Q, quinidine.
Outcomes
Primary measure
PBA episodes improved as shown by a significant reduction in mean (SD) CNS-LS score by −6.2 (6.1) at day 30 and − 7.6 (6.7) at day 90 compared with baseline ( Figure 2) . As per the planned comparison, the CNS-LS reduction at day 90 was consistent with the CNS-LS reduction for DM/Q-treated patients with ALS or MS enrolled in the 12-week, pivotal STAR trial, and was largely outside the 95% CIs for placebo results in that trial (Figure 2 ).
Secondary Measures
Compared with baseline, PBA episodes were reduced by 64.9% (95% CI: 61.7%, 67.7%) at day 30 and by 74.5% (95% CI: 71.8%, 76.9%) at day 90 (P < 0.001, both). The median 7-day PBA episode counts (min, max) decreased from 10 (0, 240) at baseline to 3 (0, 70) at day 30 and 2 (0, 73) at day 90. At study end, 32 of the 92 patients reporting episodes at baseline (34.8%) were in remission (no episodes in the prior week).
At study end, clinicians and patients/caregivers reported the patient's overall condition with respect to PBA as "much improved" or "very much improved" (74.7% CGI-C and 67.4% PGI-C, respectively; Figure 3 ). Compared with baseline, mean endpoint scores on the SIS improved significantly on all 8 domains and on the stroke recovery question ( Safety AEs were reported in 40 patients (35.4% of the safety population) and are described in Table 3 . AEs occurring in more than 2 patients (>2%) were diarrhea, headache, constipation, and dizziness. For most patients, AEs were considered mild or moderate in severity. The only reported cardiac AE was bradycardia that led to treatment discontinuation for a 75-year-old female with a history of cardiovascular disease; this patient was also taking metoprolol, a beta-blocker extensively metabolized by CYP-2D6 and thus susceptible to inhibition by quinidine. Seven serious AEs occurred in 5 patients (ie, noncardiac chest pain, pneumonia, aspiration pneumonia, facial bones fracture and fall [ Figure 3 . Clinical and patient global impression of change. *CGI-C and PGI-C are rated by the investigator and the patient/caregiver, respectively, and are 7-point scales that assess overall treatment response with respect to PBA from baseline to day 90. Effectiveness analysis population. Total sums to less than 100% because of missing data for n = 12, CGI-C; and n = 11, PGI-C. (19.8) .00 50.0 60.0 5.0 ADL = Activities of Daily Living; SD = SD; SIS = Stroke Impact Scale. * SIS domain scores range 0 to 100; higher scores indicate fewer impairments.
† P values based on 1-sample t-test assessing whether mean change is statistically different from zero.
treated with DM/Q 20/10 mg experienced improvements across multiple assessments, including significant reductions in CNS-LS scores and PBA episodes, improvements in CGI-C and PGI-C, SIS, QOL-VAS, MMSE, and PHQ-9. These results were consistent with those for other PRISM II patient cohorts with PBA following dementia or TBI [23, 24, 32] . Further, an a priori analysis comparing results from this open-label trial with results from placebocontrolled phase 3 studies enrolling patients with PBA caused by ALS or MS showed a consistent effect based on confidence intervals for change from baseline mean CNS-LS [19] [20] [21] 25] . Although treatment effects cannot be directly compared across different clinical trials, reproducible, consistent improvements in CNS-LS support DM/Q effectiveness across trials and patient types. The statistically significant improvements from baseline observed for all secondary measures demonstrate an overall reduction in PBA episode frequency and impact, supporting the primary outcome. Reported improvement on CGI-C and PGI-C, along with improvements across all SIS domains, including stroke recovery, suggest that reductions in PBA episodes may have improved overall functioning. Treatment with DM/Q 20/10 mg may also have a direct effect on poststroke function and neurologic sequelae, though no placebo arm was available for comparison here. Similarly, the QOL-VAS, PHQ-9, and overall satisfaction ratings reflect an overall improvement in perceived quality of life associated with greater control of PBA, with clinically meaningful improvement observed on the PHQ-9 [31, 33] .
Clinically meaningful improvement was also observed on the SIS mobility domain based on a previously published MCID [31, 33] . Larger mean improvements (>10 points) were reported for the SIS emotion and social participation domains, which is relevant since these domains significantly predicted patients' global assessment of recovery in a prior validation study. Although MCIDs have not been established for nonphysical domains, overall SIS changes of 10 to 15 points have been accepted as clinically meaningful based on demonstration of test-retest variability and association with score changes on the modified Rankin scale (commonly used for measuring the degree of disability or dependence in the daily activities for people following a stroke) [34] . Compared with 2 prior available longitudinal studies evaluating SIS changes over 3 to 6 months and 3 to 12 months following mild to moderate stroke, the current PBA patients had lower (worse) baseline scores and larger improvements [34, 35] . The analysis did not include an evaluation of the relationship between change in PBA measures and SIS scores; this warrants further study. DM/Q 20/10 mg was well tolerated in this trial, with few discontinuations due to AEs. Most AEs were mild or moderate in severity; few patients reported serious AEs, and no serious AE was considered treatment-related by the investigators. Only 1 patient reported a cardiac AE, bradycardia, and discontinued treatment. Further, the absence of cognitive AEs and mean improvement on MMSE and SIS memory domain is an important safety finding in this population. In fact, fewer AEs were reported compared with phase 3 DM/Q trials in patients with ALS or MS, despite broader eligibility criteria with respect to allowed comorbidities and concomitant medications. Differences in AEs likely reflect differences in morbidity among these patient populations, as well as greater tolerability with the lower DM/Q 20/10 dosage [19] [20] [21] . AEs were consistent with those reported by patients with PBA caused by stroke who participated in a 1-year study of twice-daily DM/Q 30/30 [22] .
The primary limitation of this study is the open-label design and lack of a control arm, which may have introduced expectations of treatment benefit or assessment bias. To help mitigate design limits on interpretation of efficacy findings, an a priori comparison to a comparable phase 3, placebo-controlled study was included in the methodology as a sensitivity measure, which showed treatment effects of similar magnitude; however, patients in that trial had PBA caused by MS or ALS. Similarly, the CNS-LS has been validated for use as a measure of PBA episode frequency and severity in patients with PBA caused by ALS and MS. Although a formal validation of the CNS-LS has not been conducted in a stroke population, the correspondence of CNS-LS reduction with PBA episode reduction and other secondary outcomes, as well as epidemiologic survey data showing higher CNS-LS scores to be associated with greater perceived burden of laughing and crying episodes in stroke patients suggests that this scale provided a useful measure of PBA episode frequency and severity in our sample [11] . Another potential limitation was the number of patients who completed the trial (91/113 [80.5%]); however, these are similar to the numbers who completed the overall PRISM II trial and dementia cohort and somewhat higher than the TBI cohort [25] . Lastly, no statistical corrections for multiple comparisons were performed.
Conclusion
Trial results support the use of DM/Q 20/10 mg for PBA caused by neurologic etiologies, including stroke. Openlabel treatment with DM/Q was associated with reduced PBA episodes and improved global measures of well-being and function, including measures of stroke-related disability and depressive symptoms. DM/Q appeared well tolerated, with most AEs being mild or moderate in nature. This study expands the clinical evidence for DM/Q effectiveness in treating PBA, including patients who have suffered a stroke.
